Global Navigation
|
|
|
|
- 21 MAY 2009
FDA Approves SAMSCA™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia - 15 MAY 2009
Otsuka Holdings Co., Ltd -- Fiscal Year through March 2009 - Consolidated Results（PDF:507KB） - 6 APR 2009
Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration
- 19 JUNE 2009
Otsuka Pharmaceutical Co., Ltd -- Fiscal Year through March 2009 Non-consolidated Results of Otsuka Pharmaceutical Co., Ltd. (PDF:314KB) - 19 JUNE 2009
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF:162KB) - 6 APR 2009
Otsuka Pharmaceutical Special Sponsorship Pocari Sweat U-12 Soccer League